基于神经激素系统治疗肺动脉高压进展

doi:10.19586/j.2095-2341.2023.0092

生物技术进展 ›› 2023, Vol. 13 ›› Issue (6): 889-894.DOI: 10.19586/j.2095-2341.2023.0092

• 进展评述 • 上一篇

基于神经激素系统治疗肺动脉高压进展

方学升¹^,²^,³(), 包明威¹^,²^,³()

^1.武汉大学人民医院心血管内科，武汉 430060
^2.武汉大学心血管病研究所，武汉 430060
^3.心血管病湖北省重点实验室，武汉 430060

收稿日期:2023-07-24 接受日期:2023-09-12 出版日期:2023-11-25 发布日期:2023-12-12
通讯作者: 包明威
作者简介:方学升 E-mail: 912689491@qq.com；
基金资助:
国家自然科学基金项目(81970438)

Progress on Treatment of Pulmonary Hypertension Based on Neurohormonal System

Xuesheng FANG¹^,²^,³(), Mingwei BAO¹^,²^,³()

^1.Department of Cardiology，Renmin Hospital of Wuhan University，Wuhan 430060，China
^2.Cardiovascular Research Institute of Wuhan University，Wuhan 430060，China
^3.Hubei Key Laboratory of Cardiology，Wuhan 430060，China

Received:2023-07-24 Accepted:2023-09-12 Online:2023-11-25 Published:2023-12-12
Contact: Mingwei BAO

摘要/Abstract

摘要：

肺动脉高压（pulmonary hypertension, PH）是一种进行性进展的致死性心肺疾病，最终会导致右心衰竭和死亡，其发病率和死亡率逐年上升。目前PH的发病机制尚不明确，且缺乏有效的治疗手段。最近的研究表明，在PH患者及动物模型中存在自主神经系统（autonomic nervous system, ANS）失衡和肾素-血管紧张素-醛固酮系统（renin-angiotensin-aldosterone system, RAAS）激活的现象，参与促进PH发生发展，并且与PH患者预后紧密相关。综述了针对神经激素系统的干预方法对PH的作用及相应机制，包括α/β受体阻滞剂、β3受体激动剂、肺动脉去神经、肾去神经、交感神经节阻滞、迷走神经刺激及RAAS抑制剂，以期为PH治疗提供新的手段。

关键词: 肺动脉高压, 自主神经系统, 肾素-血管紧张素-醛固酮系统

Abstract:

Pulmonary hypertension （PH） is a progressive， fatal cardiopulmonary disease， and eventually leads to death due to right heart failure. The pathogenesis of PH has not been clarified and there is a lack of effective treatment for PH. Recent studies have shown that autonomic nervous system （ANS） imbalance and renin-angiotensin-aldosterone system （RAAS） activation are found in PH patients and animal models， which are involved in promoting the occurrence and development of PH and are closely related to the prognosis of PH patients. This paper reviewed the effects and mechanisms of intervention methods targeting the neurohormonal system， including α/β blockers， β3 agonists， pulmonary artery denervation， renal denervation， sympathetic ganglion block， vagus nerve stimulation and RAAS inhibitors on PH， in order to provide a new method for the PH treatment.

Key words: pulmonary hypertension, autonomic nervous system, renin-angiotensin-aldosterone system

中图分类号:

Q189

方学升, 包明威. 基于神经激素系统治疗肺动脉高压进展[J]. 生物技术进展, 2023, 13(6): 889-894.

Xuesheng FANG, Mingwei BAO. Progress on Treatment of Pulmonary Hypertension Based on Neurohormonal System[J]. Current Biotechnology, 2023, 13(6): 889-894.

参考文献 13

1	THENAPPAN T, ORMISTON M L, RYAN J J, et al.. Pulmonary arterial hypertension: pathogenesis and clinical management[J/OL]. BMJ, 2018, 360: j5492[2023-06-26]. .
2	SIMONNEAU G, MONTANI D, CELERMAJER D S, et al.. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J/OL]. Eur. Respir. J., 2019, 53(1): 1801913[2022-11-03]. .
3	XIAO Y, CHEN P P, ZHOU R L, et al.. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review[J]. Aging Dis., 2020, 11(6): 1623-1639.
4	ZELT J G E, SUGARMAN J, WEATHERALD J, et al.. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era[J/OL]. Pulm. Circ., 2022, 59(6): 2101552[2022-10-07]. .
5	MEHRA R, TJURMINA O A, AJIJOLA O A, et al.. Research opportunities in autonomic neural mechanisms of cardiopulmonary regulation: a report from the national heart, lung, and blood institute and the national institutes of health office of the director workshop[J]. JACC Basic Transl. Sci., 2022, 7(3): 265-293.
6	VAILLANCOURT M, CHIA P, SARJI S, et al.. Autonomic nervous system involvement in pulmonary arterial hypertension[J/OL]. Eur. Respir. J., 2017, 18(1): 201[2023-06-06]. .
7	KARPOV A A, VACHRUSHEV N S, SHILENKO L A, et al.. Sympathetic denervation and pharmacological stimulation of parasympathetic nervous system prevent pulmonary vascular bed remodeling in rat model of chronic thromboembolic pulmonary hypertension[J/OL]. J. Cardiovasc. Dev. Dis., 2023, 10(2): 40[2023-06-25]. .
8	SILVA GONÇALVES BÓS D D A, VAN DER BRUGGEN C E E, KURAKULA K, et al.. Contribution of impaired parasympathetic activity to right ventricular dysfunction and pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Circulation, 2018, 137(9): 910-924.
9	CONSTANTINE A, DIMOPOULOS K. Pulmonary artery denervation for pulmonary arterial hypertension[J]. Trends Cardiovasc. Med., 2021, 31(4): 252-260.
10	ROTHMAN A, JONAS M, CASTEL D, et al.. Pulmonary artery denervation using catheter-based ultrasonic energy[J]. EuroIntervention, 2019, 15(8): 722-730.
11	MARON B A, LEOPOLD J A. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part Ⅱ: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension[J]. Circulation, 2015, 131(23): 2079-2091.
12	GARCÍA-LUNAR I, PEREDA D, IBANEZ B, et al.. Neurohormonal modulation as a therapeutic target in pulmonary hypertension[J/OL]. Cells, 2020, 9(11): 2521[2022-01-09]. .
13	YU W, GU Y, CHEN P, et al.. Norepinephrine stimulation downregulates the β(2)-adrenergic receptor-nitric oxide pathway in human pulmonary artery endothelial cells[J]. J. Cell. Physiol., 2019, 234(2): 1842-1850.

[1]	潘舟, 胡克. 线粒体功能障碍在缺氧性肺动脉高压中的作用[J]. 生物技术进展, 2023, 13(6): 882-888.
[2]	方学升, 包明威. 骨膜蛋白在心血管疾病中的研究进展[J]. 生物技术进展, 2023, 13(5): 725-729.

基于神经激素系统治疗肺动脉高压进展

Progress on Treatment of Pulmonary Hypertension Based on Neurohormonal System

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 13

相关文章 2

编辑推荐

Metrics

本文评价